Public biotech (Nasdaq: JBIO)
Appears in 1 story
Developing JADE101 for IgA nephropathy, Phase 2 underway
For decades, doctors had no drugs specifically approved for IgA nephropathy, a kidney disease that pushes up to half of patients toward kidney failure within ten years of diagnosis. Since December 2021, the FDA has approved five.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
